← Back to Search

Flavonoid

Luteolin for Schizophrenia

N/A
Recruiting
Led By Robert W Buchanan, M.D.
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Positive and Negative Syndrome Scale (PANSS) total score of 75 or more OR a Clinical Global Impression severity of illness item score of 4 or more
Treated with the same antipsychotic for at least 60 days and have received a constant therapeutic dose for at least 30 days prior to study entry
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial will test whether luteolin, a natural product found in some foods, can help improve symptoms of schizophrenia.

Who is the study for?
This trial is for adults aged 18-60 with schizophrenia or schizoaffective disorder, who have been on a stable dose of antipsychotics for at least two months. Participants must be clinically stable and not using substances (except mild marijuana use), immunosuppressives, high-dose anti-inflammatories, or have infections that could affect the study.Check my eligibility
What is being tested?
The study tests if Luteolin, a natural compound in foods like celery and parsley known for its health benefits, can improve symptoms of schizophrenia when compared to a placebo (a substance with no active drug).See study design
What are the potential side effects?
While specific side effects are not listed here, Luteolin may cause reactions related to its anti-inflammatory properties. As it's being tested against a placebo which has no treatment effect, any side effects would likely stem from Luteolin.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My mental health condition is severe, as shown by my test scores.
Select...
I've been on the same antipsychotic medication for 60 days, with a stable dose for the last 30 days.
Select...
I have been diagnosed with schizophrenia or schizoaffective disorder.
Select...
I am between 18 and 60 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cognition and oxidative stress
Cognitive impairments
Global oxidative stress
+1 more
Secondary outcome measures
Negative symptoms of schizophrenia
Positive symptoms of schizophrenia

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LuteolinActive Control1 Intervention
Group II: PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

University of California, Los AngelesOTHER
1,530 Previous Clinical Trials
10,264,627 Total Patients Enrolled
38 Trials studying Schizophrenia
4,830 Patients Enrolled for Schizophrenia
Stanley Medical Research InstituteOTHER
140 Previous Clinical Trials
10,348 Total Patients Enrolled
83 Trials studying Schizophrenia
6,286 Patients Enrolled for Schizophrenia
University of Maryland, BaltimoreLead Sponsor
688 Previous Clinical Trials
374,596 Total Patients Enrolled
66 Trials studying Schizophrenia
10,197 Patients Enrolled for Schizophrenia

Media Library

Luteolin (Flavonoid) Clinical Trial Eligibility Overview. Trial Name: NCT05204407 — N/A
Schizophrenia Research Study Groups: Luteolin, Placebo
Schizophrenia Clinical Trial 2023: Luteolin Highlights & Side Effects. Trial Name: NCT05204407 — N/A
Luteolin (Flavonoid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05204407 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still opportunities for volunteers to participate in this medical trial?

"This clinical trial is in active recruitment phase, as indicated on the official listing hosted by ClinicalTrials.gov. The protocol was uploaded to the platform on June 13th 2022 and updated for a final time this past July 22nd."

Answered by AI

Is the cutoff age for this trial restriction restricted to 25 and under?

"Candidates for this study must be aged between 18 and 60, as outlined in the inclusion criteria."

Answered by AI

Could I be a participant in this medical research?

"Enrolment in this medical trial is restricted to those aged 18-60 suffering from schizophrenia. Approximately 60 patients will be accepted into the study."

Answered by AI

For how many participants is enrollment open for this clinical trial?

"Affirmative. The research posted on clinicaltrials.gov reveals that the trial is actively recruiting for 60 enrollees from two different healthcare facilities, commencing June 13th 2022 and last updated July 22nd of this year."

Answered by AI

Who else is applying?

What state do they live in?
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Luteolin for the Treatment of People With Schizophrenia
Robert Buchanan 2022. "Luteolin for the Treatment of People With Schizophrenia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05204407.
All > Schizophrenia
~19 spots leftby Mar 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top